Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Acute kidney injury, chronic kidney function decline and the mean percent reduction in estimated glomerular filtration rate among patients after autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy.

Data availability

The data that support the findings of this study are available from the Research Patient Data Registry at Mass General Brigham, but restrictions apply as they were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission from Mass General Brigham.

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90. https://doi.org/10.1182/blood-2016-01-643569.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M. Outcomes of autologous hematopoietic cell transplantation in diffuse large B cell lymphoma refractory to firstline chemoimmunotherapy. Transpl Cell Ther. 2021;27:55 e51–55 e57. https://doi.org/10.1016/j.bbmt.2020.09.004.

    CAS  Article  Google Scholar 

  3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. https://doi.org/10.1056/NEJMoa1407222.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–54. https://doi.org/10.1056/NEJMoa1708566.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2017;130:577. https://doi.org/10.1182/blood.V130.Suppl_1.577.577.

    Article  Google Scholar 

  6. Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O’Donnell EK, Jacobson CA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020;76:63–71. https://doi.org/10.1053/j.ajkd.2019.10.011.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020;26:1071–6. https://doi.org/10.1016/j.bbmt.2020.02.012.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374:2256–67. https://doi.org/10.1056/NEJMra1404711.

    Article  PubMed  Google Scholar 

  9. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.

    CAS  Article  Google Scholar 

  10. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pr. 2012;120:c179–84. https://doi.org/10.1159/000339789.

    Article  Google Scholar 

  11. Ansari R, Caimi P, Zhengyi C, Rashidi A. Renal outcomes after chimeric antigen receptor T-cell (CAR-T) therapy: a single center perspective. Nephrol Dial Transpl. 2022. https://doi.org/10.1093/ndt/gfac048.

    Article  Google Scholar 

  12. Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transpl. 2008;8:2378–90. https://doi.org/10.1111/j.1600-6143.2008.02408.x.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This cohort includes 114 patients that were previously reported in studies of AKI after CAR-T (PMID: 33098925, 31973908).

Funding

MES is supported by the National Institutes of Health award R01 DK130839, K23DK117014, and the Claflin Distinguished Scholars award. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. These organizations were not involved in study design, analysis, interpretation, or manuscript creation.

Author information

Authors and Affiliations

Authors

Contributions

Research idea and study design: MES, MF, and PH; data acquisition: PH, DM, DH, ML, and IS; data analysis/interpretation: PH, IS, MF, SG, HS, and MES; statistical analysis: PH, TO, and MES; supervision or mentorship: MF and MES. Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s contributions, and agrees to ensure that questions about the accuracy or integrity of any portion of the work are appropriately investigated and resolved, including with documentation in the literature if appropriate.

Corresponding author

Correspondence to Meghan E. Sise.

Ethics declarations

Competing interests

PH, IS, DM, DH, HS, ML, TO, and MES have nothing to declare. MF is a consultant for Novartis, Kite/Gilead, BMS, Iovance, JnJ/Legend, and Arcellx. SG receives research funding from BTG International, GE Healthcare and NIH NIDDK K23DKDK125672.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

titles and legends per your request

Supplemental Figure 1. Patient flow

41409_2022_1767_MOESM3_ESM.png

Supplemental Figure 2. Comparison of acute kidney injury rates at 15, 30, and 90 days among patients receiving autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy

Supplemental Table 1. Baseline characteristics of the overall cohort and the subset followed for at least 12 months

41409_2022_1767_MOESM5_ESM.xlsx

Supplemental Table 2. Predictors of AKI among patients receiving autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy

41409_2022_1767_MOESM6_ESM.xlsx

Supplemental Table 3. Predictors of chronic kidney function decline among patients receiving autologous hematopoietic stem cell transplant or chimeric antigen receptor T cell therapy

41409_2022_1767_MOESM7_ESM.xlsx

Supplemental Table 4: Predictors of acute kidney injury among patients receiving chimeric antigen receptor T cell therapy

41409_2022_1767_MOESM8_ESM.xlsx

Supplemental Table 5. Predictors of chronic kidney function decline among patients receiving chimeric antigen receptor T cell therapy who survived a year.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hanna, P., Strohbehn, I., Moreno, D. et al. Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. Bone Marrow Transplant 57, 1623–1625 (2022). https://doi.org/10.1038/s41409-022-01767-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01767-7

Search

Quick links